Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.
about
Drug Resistance Is Not Directly Affected by Mating Type Locus Zygosity in Candida albicansProphylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infantsTreatment and prophylaxis of invasive candidiasisEpidemiology of invasive candidiasis: a persistent public health problemInvestigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationRapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy.Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria.Pharmacological advances in the treatment of invasive candidiasis.Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditisMechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.One year prospective survey of Candida bloodstream infections in Scotland.Incidence and predictors of invasive candidiasis associated with candidaemia in children.Antifungal drug discovery through the study of invertebrate model hosts.Microsatellite marker analysis as a typing system for Candida glabrata.Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailinPrior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.Resistance to antifungals that target CYP51.Pivotal role for a tail subunit of the RNA polymerase II mediator complex CgMed2 in azole tolerance and adherence in Candida glabrataAntimicrobial photodynamic inactivation inhibits Candida albicans virulence factors and reduces in vivo pathogenicity.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingManagement of neonatal candidiasis. Neonatal Candidiasis Study GroupCandidemia in Norway (1991 to 2003): results from a nationwide studyCandida guilliermondii fungemia in patients with hematologic malignanciesStability of allelic frequencies and distributions of Candida albicans microsatellite loci from U.S. population-based surveillance isolates.Antifungal drug resistance.Complementary amplicon-based genomic approaches for the study of fungal communities in humansEvaluation of microbial load in oropharyngeal mucosa from tannery workers.Changing strategies for the management of invasive fungal infections.In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.Retrospective analysis of mortality and Candida isolates of 75 patients with candidemia: a single hospital experience.The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole.Micafungin: the US perspective.Emerging fungal diseases.An update on antifungal targets and mechanisms of resistance in Candida albicans.
P2860
Q22337052-3A993239-39B3-4FDD-AB2A-4A19FD76DDDDQ24243140-2A2D9208-38A8-47AF-B2AE-9A9F97428200Q27001567-A458A8BA-7609-425B-959D-677E94287FD1Q29616758-B37A3B16-CFF8-4E16-9436-2AB243E3CC3CQ29994504-6B1E39B6-A75D-4F00-9059-D4E1DD343760Q30433993-F4930D3F-1577-4E56-8ADD-6D896A3486C1Q30452976-E8E4CA11-F7E5-471C-91F9-FC81ED971275Q33188024-3D18F900-63E3-4B3F-896B-DD4B346D8918Q33202199-46930A28-D5E9-48E3-86BE-84A49CA49383Q33232599-7512E1C4-9E7A-4BC6-B016-FD6E2790FA54Q33803108-856E2B2F-C6FB-46B7-BEEC-5330F3EEABC9Q33805788-82667512-09A3-48FD-B16C-1D6E45E13FE6Q33910250-CE89F39E-DFE7-40F5-B716-9D9234EBF5B9Q33926760-A1FDB631-7394-4056-A713-6E0BBF51D7D4Q34002069-0DA6BCB5-5403-4D0A-AEB0-0E2CE6DF83A1Q34042191-C7071B5D-566D-4E84-86CD-17B428EDEEDBQ34042232-358FA480-AC6C-4558-95D3-FD6D72EFFFCFQ34058099-0964850E-AAA9-4FF0-BA64-5ACAC5D6D9EAQ34110565-DD8DBB21-2ADB-4F14-A82E-7C94C2E084F1Q34123634-BAEE625A-290F-45D4-AD22-BB63DE3154CCQ34202154-F2C6B22E-B598-43D4-9895-A3747BCFB367Q34276700-7DA6AC9D-ED6B-4D35-9B0A-85867720FAA9Q34298870-FFB7D8CC-A5F3-41AC-A302-DEC11D87C5DAQ34467917-1BB0812B-4909-45E2-9392-BBD0FD1B9EA1Q34647337-6DE1ED9D-A966-44D0-B56B-15A48DD211D0Q34680771-3C9537F3-9846-400D-A31D-B4EFA97F050DQ34719299-2DB81B54-8B19-4AE6-8A2B-095D61AFDAA2Q34719843-64F8BC3B-7AA3-49A1-864A-7C92B7B34DCCQ34774903-F7631D91-E130-41FD-87D5-19022182A04DQ35040008-A6F17161-4BE2-49B7-80F0-B6C7A9780178Q35113366-FA06CD55-49E3-4D45-B180-6D02D89D44DCQ35211480-8E1427EF-703F-450D-9D59-5360233FCE8DQ35678997-509B4547-456B-48DD-A013-4EAE99FBC4A3Q35759094-365DAB01-2094-42E5-AE47-C63F70F5FCBCQ35782575-0F91993D-0169-4C13-8A6A-BDFE9A3E7568Q35848669-6DE9A457-CFEB-456E-9982-2CE993DB0636Q36095050-BB8D7063-A975-4253-B0CB-30E3BEC606D3Q36140652-19188D55-3702-43ED-91DE-4AB0BDFB6A5EQ36199785-0A8F3BDF-93B5-444E-9A19-BA4DA8AB85DCQ36235037-6C77A2EA-1C6E-44F9-8578-32CECA93CF2C
P2860
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Trends in antifungal susceptib ...... illance Program, 1997 to 2000.
@ast
Trends in antifungal susceptib ...... illance Program, 1997 to 2000.
@en
type
label
Trends in antifungal susceptib ...... illance Program, 1997 to 2000.
@ast
Trends in antifungal susceptib ...... illance Program, 1997 to 2000.
@en
prefLabel
Trends in antifungal susceptib ...... illance Program, 1997 to 2000.
@ast
Trends in antifungal susceptib ...... illance Program, 1997 to 2000.
@en
P2093
P2860
P1476
Trends in antifungal susceptib ...... eillance Program, 1997 to 2000
@en
P2093
M A Pfaller
R J Hollis
S A Messer
SENTRY Participants Group
P2860
P304
P356
10.1128/JCM.40.3.852-856.2002
P407
P577
2002-03-01T00:00:00Z